One Day Advisor

By Dr. Frank Yap, MD, MBA  · OneDayAdvisor.com · Updated November 2026 with Q3 2026 earnings (Lilly and Viking, Oct 29; Novo, Nov 4) Quick Answer Eli Lilly is the clear commercial leader among GLP-1 stocks, with Q3 2026 revenue up 39% to $24.4 billion. Novo Nordisk is the turnaround case, powered by its Wegovy pill. Viking Therapeutics is the high-risk, pre-revenue Phase 3 bet. Pfizer and Merck offer smaller, later-stage GLP-1 exposure inside diversified pharma. All five carry pricing, trial and competition risk. Disclosure This article is educational and is not personalized investment advice. It contains no affiliate links or paid placements. Prices and guidance change quickly; verify figures with company filings before acting. Past performance does not predict future results. Contents Snapshot table How to think about GLP-1 stocks 1. Eli Lill...

Home › Pharma › GLP-1 Investing Hub By OneDayAdvisor Editorial Team  |  Published: October 14, 2026  |  Last updated: November 2026 (company results through Novo Nordisk’s Nov 4 report) QUICK ANSWER GLP-1 investing in November 2026 turns on volume growth against falling prices. Lilly’s Q3 revenue rose 39% to $24.4 billion and its 2026 guidance rose to $91–92 billion; Novo’s adjusted sales rose 4%, led by the Wegovy pill (DKK 5.39 billion), and its outlook now spans −2% to +2%. The key questions are valuation, price erosion, Medicare policy and pipeline timing, including CagriSema’s FDA decision and retatrutide’s 2027 filing, not whether demand exists. [1] [2] Disclosure. This article is educational research, not investment, tax or medical advice. OneDayAdvisor is not a registered investment adviser, and n...